Core Viewpoint - WuXi Biologics (02269.HK) is set to participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2024, where it will present updates on its business operations and financial performance [1] Group 1: Business Performance - The company reported a strong business and financial performance, with 209 new projects expected in 2025, bringing the total to 945 projects, including 74 in Phase III clinical trials and 25 CMO (Contract Manufacturing Organization) projects [1] - The research platform continues to show robust momentum, with record upfront and total payments in 2025, and new research contracts with potential milestone payments exceeding $4 billion [1] Group 2: Market Opportunities - Two-thirds of the new projects are focused on bispecific antibodies, multispecific antibodies, and ADCs (Antibody-Drug Conjugates), which are expected to drive innovation and open exciting market opportunities for the company [1] - The company completed 28 PPQ (Process Performance Qualification) projects in 2025, with 34 PPQ projects confirmed as of the announcement date in 2024, indicating a continuous increase in project activity [1] Group 3: Future Outlook - The company expresses confidence in maintaining growth momentum into 2026 and remains optimistic about its future prospects [1]